| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
BRD5529 exhibits strong CARD9-TRIM62 inhibitory activity that is dose-dependent, with an IC50 of 8.6 μM[1]. In vitro, BRD5529 binds CARD9 directly and disrupts its ubiquitination, while TRIM62 is not bound by it [1]. In vitro, TRIM62-mediated CARD9 ubiquitination is dose-dependently inhibited by BRD5529 (40 μM) [1]. Innate immune cells' CARD9-dependent signaling is inhibited by BRD5529 (200 μM, 0–50 minutes; 200 μM, 2-4 hours) [1].
|
|---|---|
| ln Vivo |
The initial general safety and toxicological investigation of BRD5529 (ip; 0.1 or 1.0 mg/kg; daily for 2 weeks) revealed no inherent safety issues [2].
|
| Cell Assay |
Western Blot analysis [1]
Cell Types: HEK293F Cell Tested Concentrations: 40 μM Incubation Duration: Experimental Results: Inhibition of CARD9 ubiquitination reaction in vitro. |
| Animal Protocol |
Animal/Disease Models: Pneumocystis pneumonia (PCP) model [2]
Doses: 0.1 or 1.0 mg/kg Route of Administration: intraperitonealdaily for 2 weeks Experimental Results: No significant changes in daily or final body weight gain, Proinflammatory cytokines demonstrated no significant differences in changes. Pathological scores demonstrated no obvious changes in the lungs, liver, and kidneys. |
| References |
| Molecular Formula |
C25H31N5O4
|
|---|---|
| Molecular Weight |
465.54474568367
|
| Exact Mass |
465.237
|
| CAS # |
1358488-78-4
|
| PubChem CID |
83288403
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
-0.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
34
|
| Complexity |
740
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1(CCN(C2C(C(=O)O)=CC(=CN=2)NC(C2C=CC(C)=CC=2)=O)CC1)N1CCCCC1)N
|
| InChi Key |
ZXWHESBABUHJBE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H31N5O4/c1-17-5-7-18(8-6-17)22(31)28-19-15-20(23(32)33)21(27-16-19)29-13-9-25(10-14-29,24(26)34)30-11-3-2-4-12-30/h5-8,15-16H,2-4,9-14H2,1H3,(H2,26,34)(H,28,31)(H,32,33)
|
| Chemical Name |
2-(4-carbamoyl-4-piperidin-1-ylpiperidin-1-yl)-5-[(4-methylbenzoyl)amino]pyridine-3-carboxylic acid
|
| Synonyms |
BRD-5529; BRD 5529; BRD5529
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~268.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 20 mg/mL (42.96 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1480 mL | 10.7402 mL | 21.4804 mL | |
| 5 mM | 0.4296 mL | 2.1480 mL | 4.2961 mL | |
| 10 mM | 0.2148 mL | 1.0740 mL | 2.1480 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
